help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_3, 4-10, May 2008; doi:10.1634/theoncologist.13-S3-4
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gascón, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gascón, P.

Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications

Pere Gascón

Medical Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

Key Words. Erythropoiesis-stimulating agents • ESAs • Anemia • Safety • Survival

Correspondence: Pere Gascón, M.D., Ph.D., Hospital Clinic, Division of Medical Oncology, IDIBAPS, Institut Clinic Malalties Hemato-Oncològiques (ICMHO), University of Barcelona, 08036 Barcelona, Spain. Telephone: 34-932275402; Fax: 34-934546520; e-mail: gascon{at}clinic.ub.es

Disclosure: The author has received honoraria for lecturing from Roche Pharma, Amgen, and Janssen-Cilag, manufacturers of epoetin beta, darbepoetin alfa, and epoetin alfa, respectively. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Certain studies in which erythropoiesis-stimulating agents (ESAs) have been given not with the aim of correcting anemia but to achieve higher target levels of hemoglobin have shown significantly poorer survival among treated patients. However, studies in which ESAs were administered with the aim of reducing the need for RBC transfusions in patients with chemotherapy-associated anemia demonstrate that the use of these agents is not associated with any adverse effect on survival when compared with placebo controls. We can therefore be reassured that using ESAs within the labeled indications will not adversely affect patient outcome.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. S. Aapro
Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk-Benefit Update
Oncologist, May 1, 2008; 13(suppl_3): 1 - 3.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.